Beijing Sun-Novo Pharmaceutical Research (688621) Stock Overview
A contract research company, engages in the research and development of drugs in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
688621 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥66.04 |
| 52 Week High | CN¥86.50 |
| 52 Week Low | CN¥33.00 |
| Beta | 0.20 |
| 1 Month Change | -11.73% |
| 3 Month Change | 33.23% |
| 1 Year Change | 51.64% |
| 3 Year Change | 16.15% |
| 5 Year Change | n/a |
| Change since IPO | -23.01% |
Recent News & Updates
Recent updates
Market Might Still Lack Some Conviction On Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHSE:688621) Even After 31% Share Price Boost
Feb 20
Investors Still Aren't Entirely Convinced By Beijing Sun-Novo Pharmaceutical Research Co., Ltd.'s (SHSE:688621) Earnings Despite 40% Price Jump
Oct 02Concerns Surrounding Beijing Sun-Novo Pharmaceutical Research's (SHSE:688621) Performance
Sep 05Market Still Lacking Some Conviction On Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHSE:688621)
Jul 31We Think Beijing Sun-Novo Pharmaceutical Research (SHSE:688621) Can Stay On Top Of Its Debt
May 29Shareholder Returns
| 688621 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | -0.9% | 5.3% | 1.8% |
| 1Y | 51.6% | 62.5% | 24.1% |
Return vs Industry: 688621 underperformed the CN Life Sciences industry which returned 62.4% over the past year.
Return vs Market: 688621 exceeded the CN Market which returned 24.1% over the past year.
Price Volatility
| 688621 volatility | |
|---|---|
| 688621 Average Weekly Movement | 9.0% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in CN Market | 9.0% |
| 10% least volatile stocks in CN Market | 3.0% |
Stable Share Price: 688621's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 688621's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,359 | Yujing Liu | www.sun-novo.com |
Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of drugs in China. The company operates external preparation platform that focuses on the research and development of new drugs and generic drugs for skin external preparations; children's clinical data bridging research center; pediatric drug research and development platform; pediatric drug delivery dosage research and development platform; respiratory tract drug delivery and topical preparation platforms; polypeptide and other drug molecular design and development platform; genotoxic impurity detection platform; technology platform for slow and controlled release preparations; drug synthesis platform; and synthesis technology platform. It also offers SMO, clinical quality management, data management and statistical analysis, project management, test center, clinical research center, clinical trials, TMFDocument management, quality control, Medical Writing, medical monitoring, and pharmacovigilance services; and registration-related services for chemical drugs, biological products, and medical device products.
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Fundamentals Summary
| 688621 fundamental statistics | |
|---|---|
| Market cap | CN¥7.22b |
| Earnings (TTM) | CN¥158.67m |
| Revenue (TTM) | CN¥1.11b |
Is 688621 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688621 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.11b |
| Cost of Revenue | CN¥575.15m |
| Gross Profit | CN¥530.76m |
| Other Expenses | CN¥372.09m |
| Earnings | CN¥158.67m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 30, 2025
| Earnings per share (EPS) | 1.45 |
| Gross Margin | 47.99% |
| Net Profit Margin | 14.35% |
| Debt/Equity Ratio | 48.6% |
How did 688621 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/04 21:58 |
| End of Day Share Price | 2025/09/30 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yinglan Shu | Haitong International Research Limited |
| Yuan Yuan Sun | Industrial Securities Co. Ltd. |
| Jiaqi Zhu | Zhongtai Securities Co. Ltd. |